Two infections — influenza followed by COVID-19 — were trigger events for separate episodes of atypical hemolytic uremic syndrome…
Steve Bryson, PhD
Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Steve Bryson, PhD
For this year’s aHUS Awareness Day — held annually on Sept. 24 — advocates worldwide will focus on managing the…
Adults with atypical hemolytic uremic syndrome (aHUS) who start Soliris (eculizumab) within seven days after their symptoms start…
A previously healthy 20-year-old woman developed atypical hemolytic uremic syndrome (aHUS) after having surgery to remove her gallbladder shortly…
A 60-year-old man with atypical hemolytic uremic syndrome (aHUS) was successfully treated with Soliris (eculizumab) using a personalized…
At the onset of atypical hemolytic uremic syndrome (aHUS) among children in India, high levels of antibodies against a…
A COVID-19 vaccine may have triggered the development of two autoimmune diseases, atypical hemolytic uremic syndrome (aHUS) and antineutrophil…
Genetic screening of a large group of people suspected of having atypical hemolytic uremic syndrome (aHUS) detected very few…
Areas of brain damage caused by a lack of blood supply were found in a patient with atypical hemolytic…
Treatment with the drug Soliris (eculizumab) for atypical hemolytic uremic syndrome (aHUS) initially failed to ease the symptoms…